RxDoctor Payments Data

Paul Smith, MD

Internal Medicine · New York, NYNPI 1861595720

Payments from drug & device makers

$30,178in general payments, 2019–2025

Across 279 payments — averaging $108.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$26K
  • Viiv Healthcare Company$1K
  • Merck$728
  • Janssen Products, LP$228
  • AstraZeneca$200
  • Medtronic$193
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$2,0007%
  • Speaking & faculty fees$20,53068%
  • Travel & lodging$1,7336%
  • Food & beverage$5,65319%
  • Education$2621%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,178 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$93,302
Medicare patients
191
Services billed
1,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$70,089
BiktarvyBictegrav/Emtricit/Tenofov Ala12$54,466
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,447
NorvascAmlodipine Besylate11$2,740
ValacyclovirValacyclovir Hcl24$1,283
Atorvastatin Calcium111$999
Albuterol Sulfate HfaAlbuterol Sulfate36$785
Testosterone13$776
Amlodipine Besylate76$700
Rosuvastatin Calcium61$530
Losartan Potassium51$472
Pantoprazole Sodium11$449
Escitalopram Oxalate26$445
Levothyroxine Sodium36$379
Metoprolol Succinate28$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$26,486$54,46612 claims
GSKTrelegy Ellipta$193$6,44711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →